Life Sciences Tools and Services
Company Overview of SemBioSys Genetics Inc.
SemBioSys Genetics Inc., a development stage biotechnology company, engages in the development, manufacture, and commercialization of healthy living, animal health, and pharmaceutical products. The company develops products through its patented plant seed based oilbody genetic expression and manufacturing technology platforms. Its products include Biosimilar Insulin, which is derived from genetically engineered safflower for the treatment of diabetes; and apolipoprotein AIMilano, a human protein to reduce, stabilize, and reverse the formation of vascular atherosclerotic plaque for the prevention and treatment of cardiovascular disease. The company’s products also comprise gamma linolenic aci...
2985-23rd Avenue NE
Calgary, AB T1Y 7L3
Key Executives for SemBioSys Genetics Inc.
Vice President of Operations and Legal Affairs
President of Us and International Operations
Director of Business Development
Compensation as of Fiscal Year 2013.
SemBioSys Genetics Inc. Key Developments
SemBioSys Genetics Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012
May 16 12
SemBioSys Genetics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported net loss of $1,352,301 or $0.03 per basic and diluted share compared to $4,633,771 or $0.09 per basic and diluted share for the same period last year. Revenue was $207 compared to $50,000 for the same period last year. Operating loss was $1,254,067 compared to $1,451,785 for the same period last year. Net cash used in operating activities was $496,100 compared to $973,598 for the same period last year. The decrease of net cash used in operating activities is primarily due to the collection of a scientific research & experimental development tax credit refund of $223,902 and an increase in the payable balance.
SemBioSys Provides Update Regarding Voluntary Delisting From TSX
Apr 30 12
SemBioSys Genetics Inc. provided an update on the voluntary delisting of its common shares from the Toronto Stock Exchange (TSX) previously disclosed on April, 4, 2012. As noted in the Company's press release of April 4, 2012, the Company will voluntarily delist from the TSX and has provided the TSX with all the necessary documents to transact this orderly. The Company's lack of funds and uncertainty to exist as a going concern will not allow it to list on another stock exchange. The Company's securities will remain listed on the TSX until the end of trading on May 1, 2012, to provide potential liquidity to its shareholders prior to delisting. Each of the directors of the Company has resigned with effective May 1, 2012.
SemBioSys Genetics Inc. Announces to Approve Amendment to the Articles of Incorporation
Apr 5 12
SemBioSys Genetics Inc. announced that at the annual general meeting to be held on May 9, 2012, the shareholders to approve the amendment to the articles of incorporation of the company to consolidate its issued and outstanding common shares on the basis of a ratio within the range of one post-consolidation Common Share for every eight pre-consolidation common shares to one post-consolidation Common Share for every thirty pre-consolidation Common Shares, with the ratio to be selected and implemented by the Board of Directors in its sole discretion, if at all, at any time prior May 9, 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|